Biotest GmbH & Co. KGaA (HAM:BIO0)

Market Cap	1.27B
Revenue (ttm)	635.20M -18.8%
Net Income	-24.50M
EPS	-0.63
Shares Out	39.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.04 (0.12%)
Ex-Dividend Date	n/a

Volume	6,284
Open	32.20
Previous Close	32.30
Day's Range	32.20 - 32.20
52-Week Range	28.00 - 35.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Biotest GmbH & Co. KGaA

Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalov...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1946
• Employees: 2,495
• Stock Exchange: Hamburg Stock Exchange
• Ticker Symbol: BIO0

Financial Performance

In 2024, Biotest GmbH & Co. KGaA's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.